Action Behavior Centers Establishes the Action Institute for Outcomes Research Led by Dr. Linda LeBlanc
AUSTIN, TX / ACCESSWIRE / June 21, 2024 / Action Behavior Centers is thrilled to announce the establishment of the...
News
U.S. Electronic Medical Records (EMR) Market Insights Report 2024-2029 Featuring Prominent Vendors – Epic Systems Praxis EMR, Oracle, eClinicalWorks, MEDITECH, Veradigm – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "U.S. Electronic Medical Records (EMR) Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The...
BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 21, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) ("BioHarvest" or...
NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
LEXINGTON, KY / ACCESSWIRE / June 21, 2024 / NX Development Corp. (NXDC) is pleased to announce a significant milestone....
iRCM Inc: Trusted Experts in End-to-End Medical Billing and Credentialing Services Nationwide
"Healthcare providers often find themselves balancing the demands of patient care with the complexities of medical billing and credentialing," said...
Black Book Unveils 2024’s Top Client-Rated Financial & RCM Solutions Leading Digital Transformation and Liquidity Management
LAS VEGAS, NV / ACCESSWIRE / June 21, 2024 / Inflation, medical revenue losses, staffing challenges, and the slow recovery...
AGAPE ATP Corporation Explores Energy-Saving Solutions with B&H Intec Solutions
KUALA LUMPUR, MALAYSIA / ACCESSWIRE / June 21, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is delighted to announce the...
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related...
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to...
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes...
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscapeDOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025Projected...
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic...
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of...
Atlantic International Corp. Acquires Lyneer Staffing Solutions
Creates National Strategic Staffing, Outsourced Services and Workforce Solutions Company with Over $400 Million in Revenues for the 12 Months...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose...
Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a...
SQUID pries open AI black box
COLD SPRING HARBOR, N.Y., June 21, 2024 /PRNewswire/ -- Artificial intelligence continues to squirm its way into many aspects of...
Cenegenics Improves Operational Efficiency with Domo
SILICON SLOPES, Utah--(BUSINESS WIRE)--Domo (Nasdaq: DOMO) announced today that Cenegenics, a leader in the performance health technology industry, now uses...